Anti-fibrotic Effects and Mechanism of Shengmai Injection (生脉注射液) on Human Hepatic Stellate Cells LX-2

  • Yi Zhang
  • Li-tian Ma
  • Jie Li
  • Yu Qiao
  • Jun-ye Liu
  • Jin Wang
  • Qin-you Ren
  • Jin-tao Hu
  • Jin ZhengEmail author
Original Article



To investigate the effects of Shengmai Injection (生脉注射液, SMI) on the proliferation, apoptosis and N-myc downstream-regulated gene 2 (NDRG2, a tumour suppressor gene) expression in varying densities of human hepatic stellate cells LX-2.


LX-2 cells were cultured in vitro. Then, cells were plated in 96-well plates at an approximate density of 2.5×104 cells/mL and cultured for 48, 72, 96 or 120 h followed by the application of different concentrations of SMI (0.6, 1.2, 2.4, 4.8 or 6 μL/mL). Cell proliferation was measured after an additional 24 or 48 h using the 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The effects of SMI on different cell growth states (cultured for 48, 72, 96, or 120 h) were observed by light microscopy at 24 h after treatment. When the cells reached 80% confluence, apoptosis was detected by flow cytometry after 24 h. Lastly, LX-2 cells were treated with different concentrations of SMI and extracted with protein lysis buffer. The levels of NDRG2 were measured by Western blot.


When the LX-2 cells grew for 48, 72, 96 and 120 h, 4.8 and 6 μL/mL of SMI significantly inhibited cell proliferation at 24 and 48 h after treatment (P<0.05). And 2.4 μL/mL of SMI also inhibited cell proliferation at 24 h after treatment when cell growth for 48 h (P<0.05) and at 48 h after treatment when cell growth for 72, 96 and 120 h (P<0.05). The NDRG2 expression level in the LX-2 cell was significantly increased when treated with SMI at concentrations of 1.2, 2.4, 4.8 or 6 μL/mL (P<0.05).


The inhibitory effects of SMI on the proliferation of LX-2 cells were related to not only concentration dependent but also cell density. In addition, SMI (2.4, 4.8 and 6 μL/mL) could accelerate apoptosis in LX-2 cells, and the mechanism might be associated with NDRG2 over-expression.


Shengmai Injection liver fibrosis N-myc downstream-regulated gene 2 LX-2 cell proliferation apoptosis Chinese medicine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



We sincerely thank Prof. BIAN Hui-jie from the Fourth Military Medical University for donating LX-2 cell lines, and thank Dr. BAI Yang and Dr. ZHANG Ge from the Fourth Military Medical University for revising the manuscript. We also thank all of our colleagues for their generous support.


  1. 1.
    Li F, Ma N, Zhao R, Wu G, Zhang Y, Qiao Y, et al. Overexpression of miR–483–5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF–beta stimulated HSCs in transgenic mice. J Cell Mol Med 2014;18:966–974.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gou X, Tao Q, Feng Q, Peng J, Zhao Y, Dai J, et al. Urine metabolic profile changes of CCl4–liver fibrosis in rats and intervention effects of Yi Guan Jian Decoction using metabonomic approach. BMC Complement Altern Med 2013;13:123.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    D'Argenio G, Amoruso DC, Mazzone G, Vitaglione P, Romano A, Ribecco MT, et al. Garlic extract prevents CCl4–induced liver fibrosis in rats: the role of tissue transglutaminase. Dig Liver Dis 2010;42:571–577.CrossRefPubMedGoogle Scholar
  4. 4.
    Fan WM, Shi BY. Advances in studies on apoptotic factors of hepatic stellate cell. Med Recapitul (Chin) 2012;18:1797–1799.Google Scholar
  5. 5.
    Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin–3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006;103:5060–5065.CrossRefPubMedGoogle Scholar
  6. 6.
    Huang CL, Zhao WX. Progress on treating hepatic fibrosis in Chinese medicine. Clin J Chin Med (Chin) 2014;2:146–147.Google Scholar
  7. 7.
    Yang Q, Feng Y, Jiang SL. Experiences of Prof. YAO Xixian in treating chronic hepatic fibrosis based on blood stasis theory. Chin J Chin Med Pharm (Chin) 2007;22:168–171.Google Scholar
  8. 8.
    Cheng Y, Mai JY, Wang MF, Chen GF, Ping J. Antifibrotic effect of total flavonoids of Astmgali Radix on dimethylnitrosamine–induced liver cirrhosis in rats. Chin J Integr Med 2017;23:48–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Liu P. Inhibition of pathological angiogenesis of Chinese medicine against liver fibrosis. Chin J Integr Med 2016;22:569–572.CrossRefPubMedGoogle Scholar
  10. 10.
    Xuan J. Clinical study of Huagan Tongluo Recipe and the mechanism of Th17 cell differentiation involved in hepatic fibrosis. Nanjing: Nanjing University of Chinese Medicine;2018.Google Scholar
  11. 11.
    Deng ZJ, ed. Formulas of Chinese medicine. Beijing: China Press of Traditional Chinese Medicine;2011:152–153.Google Scholar
  12. 12.
    Rong XF, Yao WY. Influence of Shenmai Injection combined with Puerarin Injection on liver fibrosis indexes in patients with cirrhosis. World Chin J Digestol (Chin) 2006;14:3326–3329.CrossRefGoogle Scholar
  13. 13.
    Wang L, Liu N, Yao L, Li F, Zhang J, Deng Y, et al. NDRG2 is a new HIF–1 target gene necessary for hypoxia–induced apoptosis in A549 cells. Cell Physiol Biochem 2008;21:239–250.CrossRefPubMedGoogle Scholar
  14. 14.
    Shen L, Zhao ZY, Wang YZ, Ji SP, Liu XP, Liu XW, et al. Immunohistochemical detection of NDRG2 in the mouse nervous system. Neuroreport 2008;19:927–931.CrossRefPubMedGoogle Scholar
  15. 15.
    Boulkroun S, Fay M, Zennaro MC, Escoubet B, Jaisser F, Blot–Chabaud M, et al. Characterization of rat NDRG2 (N–Myc downstream regulated gene 2), a novel early mineralocorticoidspecific induced gene. J Biol Chem 2002;277:31506–31515.CrossRefPubMedGoogle Scholar
  16. 16.
    Zheng J, Li Y, Yang J, Liu Q, Shi M, Zhang R, et al. NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression. BMC Cancer 2011;11:251.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yang J, Zheng J, Wu L, Shi M, Zhang H, Wang X, et al. NDRG2 ameliorates hepatic fibrosis by inhibiting the TGFbeta1/Smad pathway and altering the MMP2/TIMP2 ratio in rats. PLoS One 2011;6:e27710.CrossRefGoogle Scholar
  18. 18.
    Yang JD. Expression of NDRG2 in liver injury–repair and preliminary study on its function. Xi'an: The Fourth Military Medical University;2013.Google Scholar
  19. 19.
    Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX–1 and LX–2: new tools for analysis of hepatic fibrosis. Gut 2005;54:142–151.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol 2014;20:7312–7324.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Duval F, Moreno–Cuevas JE, González–Garza MT, Rodríguez–Montalvo C, Cruz–Vega DE. Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis. Chin Med 2014;9:27.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis–related liver fibrosis. Int J Mol Sci 2014;15:10578–10604.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Hu W, Fan C, Jiang P, Ma Z, Yan X, Di S, et al. Emerging role of N–myc downstream–regulated gene 2 (NDRG2) in cancer. Oncotarget 2016;7:209–223.PubMedGoogle Scholar
  24. 24.
    Yoon SH, Nam YM, Hong JT, Kim SJ, Ko SK. Modification of ginsenoside composition in red ginseng (Panax ginseng) by ultrasonication. J Ginseng Res 2016;40:300–303.CrossRefPubMedGoogle Scholar
  25. 25.
    Yao C, Shi X, Lin X, Shen L, Xu D, Feng Y. Increased cardiac distribution of mono–PEGylated Radix Ophiopogonis polysaccharide in both myocardial infarction and ischemia/reperfusion rats. Int J Nanomed 2015;10:409–418.Google Scholar
  26. 26.
    Szopa A, Ekiert R, Ekiert H. Current knowledge of Schisandra chinensis (Turcz.) Baill. (Chinese magnolia vine) as a medicinal plant species: a review on the bioactive components, pharmacological properties, analytical and biotechnological studies. Phytochem Rev 2017;16:195–218.CrossRefPubMedGoogle Scholar
  27. 27.
    Liu X, Tan W, Yang F, Wang Y, Yue S, Wang T, et al. Shengmai Injection reduces apoptosis and enhances angiogenesis after myocardial ischaemia and reperfusion injury in rats. Biomed Pharmacother 2018;104:629–636.CrossRefPubMedGoogle Scholar
  28. 28.
    Yang H, Li L, Zhou K, Wang Y, Guan T, Chai C, et al. Shengmai Injection attenuates the cerebral ischemia/reperfusion induced autophagy via modulation of the AMPK, mTOR and JNK pathways. Pharm Biol 2016;10:2288–2297.CrossRefGoogle Scholar
  29. 29.
    Duan B, Xie J, Rui Q, Zhang W, Xi Z. Effects of Shengmai Injection add–on therapy to chemotherapy in patients with non–small cell lung cancer: a meta–analysis. Support Care Cancer 2018;26:2103–2111.CrossRefPubMedGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2018

Authors and Affiliations

  • Yi Zhang
    • 1
  • Li-tian Ma
    • 1
  • Jie Li
    • 2
  • Yu Qiao
    • 3
    • 4
  • Jun-ye Liu
    • 5
  • Jin Wang
    • 5
  • Qin-you Ren
    • 1
  • Jin-tao Hu
    • 6
  • Jin Zheng
    • 1
    Email author
  1. 1.Department of Traditional Chinese Medicine, Tangdu HospitalThe Fourth Military Medical UniversityXi’anChina
  2. 2.Department of EndocrinologyThe 986 Hospital of The People’s Liberation ArmyXi’anChina
  3. 3.Department of Anatomy and K.K. Leung Brain Research CenterThe Fourth Military Medical UniversityXi’anChina
  4. 4.Student BrigadeThe Fourth Military Medical UniversityXi’anChina
  5. 5.Department of Radiation MedicineThe Fourth Military Medical UniversityXi’anChina
  6. 6.Department of ImmunologyThe Fourth Military Medical UniversityXi’anChina

Personalised recommendations